Note the timeline
$Fulcrum Therapeutics (FULC.US)$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
JESSE JAMES8832 : might be something
Trytosaveabit OP JESSE JAMES8832 : Yup! I will be looking to see where it starts to consolidate over the next couple weeks. Then start scaling in!